These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 1688087)

  • 21. Synergistic antiproliferative effect of human interferons in combination with mismatched double-stranded RNA on human tumor cells.
    Hubbell HR
    Int J Cancer; 1986 Mar; 37(3):359-65. PubMed ID: 2419265
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiviral activity of mismatched double-stranded RNA against human immunodeficiency virus in vitro.
    Montefiori DC; Mitchell WM
    Proc Natl Acad Sci U S A; 1987 May; 84(9):2985-9. PubMed ID: 3106982
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-human immunodeficiency virus effects of zidovudine in combination with double-stranded RNA poly I poly C in T cells and monocytes-macrophages.
    Gochi K; Sinet M; Dazza MC; Dameron G; Brun-Vezinet F
    AIDS Res Hum Retroviruses; 1992 Jul; 8(7):1215-9. PubMed ID: 1520535
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biologic effects after a single dose of poly(I):poly(C12U) in healthy volunteers.
    Hendrix CW; Margolick JB; Petty BG; Markham RB; Nerhood L; Farzadegan H; Ts'o PO; Lietman PS
    Antimicrob Agents Chemother; 1993 Mar; 37(3):429-35. PubMed ID: 7681656
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer.
    Jasani B; Navabi H; Adams M
    Vaccine; 2009 May; 27(25-26):3401-4. PubMed ID: 19200817
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Inhibition of alfa interferon and ampligen of human immunodeficiency virus (HIV) replication in monocyte-macrophage subpopulations].
    Bergamini A; Ercoli L; Perno CF
    Medicina (Firenze); 1990; 10(1):34-6. PubMed ID: 2381279
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sensitivities of human glioma cell lines to interferons and double-stranded RNAs individually and in synergistic combinations.
    Dick RS; Hubbell HR
    J Neurooncol; 1987; 5(4):331-8. PubMed ID: 2450181
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A clinical grade poly I:C-analogue (Ampligen) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro.
    Navabi H; Jasani B; Reece A; Clayton A; Tabi Z; Donninger C; Mason M; Adams M
    Vaccine; 2009 Jan; 27(1):107-15. PubMed ID: 18977262
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical studies with ampligen (mismatched double-stranded RNA).
    Brodsky I; Strayer DR; Krueger LJ; Carter WA
    J Biol Response Mod; 1985 Dec; 4(6):669-75. PubMed ID: 4087035
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New "ThetaSwitch" drug may increase long-term survival in HIV disease.
    J Int Assoc Physicians AIDS Care; 1996 Apr; 2(4):59. PubMed ID: 11363523
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preclinical studies with Ampligen (mismatched double-stranded RNA).
    Carter WA; Strayer DR; Hubbell HR; Brodsky I
    J Biol Response Mod; 1985 Oct; 4(5):495-502. PubMed ID: 4078595
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Markers for HIV-disease progression in untreated patients and patients receiving AZT: evaluation of viral activity, AZT resistance, serum cholesterol, beta 2-microglobulin, CD4+ cell counts, and HIV antigen.
    Rübsamen-Waigmann H; Schröder B; Biesert L; Bauermeister CD; von Briesen H; Suhartono H; Zimmermann F; Brede HD; Regeniter A; Gerte S
    Infection; 1991; 19 Suppl 2():S77-82. PubMed ID: 1673119
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Studies of zidovudine in combination with didanosine and zalcitabine.
    Jablonowski H
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S52-6. PubMed ID: 8595509
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiviral activity of a synthetic double-stranded polyribonucleotide interferon inducer in a murine AIDS retrovirus model. Role of augmentation of natural killer cell activity and synergy with oral AZT.
    Black PL; McKinnon KM; Wooden SL; Ussery MA
    Ann N Y Acad Sci; 1993 Jun; 685():467-70. PubMed ID: 8363255
    [No Abstract]   [Full Text] [Related]  

  • 35. Ampligen trials.
    Am Fam Physician; 1990 Oct; 42(4):1123. PubMed ID: 2088344
    [No Abstract]   [Full Text] [Related]  

  • 36. The prognostic significance of serum viral load, codon 215 reverse transcriptase mutation and CD4+ T cells on progression of HIV disease in a double-blind study of thymopentin.
    Merigan TC; Hirsch RL; Fisher AC; Meyerson LA; Goldstein G; Winters MA
    AIDS; 1996 Feb; 10(2):159-65. PubMed ID: 8838703
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cyclic AMP mediates the direct antiproliferative action of mismatched double-stranded RNA.
    Hubbell HR; Boyer JE; Roane P; Burch RM
    Proc Natl Acad Sci U S A; 1991 Feb; 88(3):906-10. PubMed ID: 1846967
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative studies of ampligen (mismatched double-stranded RNA) and interferons.
    Carter WA; Hubbell HR; Krueger LJ; Strayer DR
    J Biol Response Mod; 1985 Dec; 4(6):613-20. PubMed ID: 2418160
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiviral action of polyadenylic-polyuridylic acid against HIV in cell cultures.
    Laurent-Crawford AG; Krust B; Deschamps de Paillette E; Montagnier L; Hovanessian AG
    AIDS Res Hum Retroviruses; 1992 Feb; 8(2):285-90. PubMed ID: 1540414
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.
    Fischl MA; Richman DD; Hansen N; Collier AC; Carey JT; Para MF; Hardy WD; Dolin R; Powderly WG; Allan JD
    Ann Intern Med; 1990 May; 112(10):727-37. PubMed ID: 1970466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.